BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma B, Zhang L, Sun L, Xin Z, Kumaravel G, Marcotte D, Chodaparambil JV, Wang Q, Wehr A, Jing J, Hong VS, Wang T, Huang C, Shao Z, Mi S. Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546. ACS Med Chem Lett 2021;12:1124-9. [PMID: 34267882 DOI: 10.1021/acsmedchemlett.1c00211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Banerjee S, Lee S, Norman DD, Tigyi GJ. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis. Molecules 2022;27:5487. [DOI: 10.3390/molecules27175487] [Reference Citation Analysis]
2 Kelly AM, Berry MR, Tasker SZ, McKee SA, Fan TM, Hergenrother PJ. Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy. J Am Chem Soc 2022;144:12367-80. [PMID: 35759775 DOI: 10.1021/jacs.2c03944] [Reference Citation Analysis]
3 Roy A, Sarkar T, Datta S, Maiti A, Chakrabarti M, Mondal T, Mondal C, Banerjee A, Roy S, Mukherjee S, Muley P, Chakraborty S, Banerjee M, Kundu M, Roy KK. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor. Chem Biol Drug Des 2021. [PMID: 34951520 DOI: 10.1111/cbdd.14017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]